18.57 -0.32 (-1.69%) | 02-12 18:48 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 23.6 ![]() |
1-year : | 25.5 |
Resists | First : | 20.2 ![]() |
Second : | 21.84 |
Pivot price | 19.87 ![]() |
|||
Supports | First : | 17.56 ![]() |
Second : | 14.61 ![]() |
MAs | MA(5) : | 19.57 ![]() |
MA(20) : | 19.88 ![]() |
MA(100) : | 20.27 ![]() |
MA(250) : | 23.63 ![]() |
|
MACD | MACD : | -0.2 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 27.8 ![]() |
D(3) : | 37.7 ![]() |
RSI | RSI(14): 40.3 ![]() |
|||
52-week | High : | 36.72 | Low : | 17.04 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ARWR ] has closed below the lower bollinger band by 2.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ARWR ] is to continue within current trading range. It is unclear right now based on current values. 47.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 18.63 - 18.78 | 18.78 - 18.88 |
Low: | 17.27 - 17.43 | 17.43 - 17.54 |
Close: | 18.35 - 18.61 | 18.61 - 18.79 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Wed, 12 Feb 2025
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2025 Earnings Call Transcript - MSN
Tue, 11 Feb 2025
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ... - Yahoo Finance
Tue, 11 Feb 2025
abrdn plc Acquires 48,929 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Mon, 10 Feb 2025
Arrowhead Pharmaceuticals Inc. (ARWR) reports earnings - Quartz
Mon, 10 Feb 2025
Arrowhead Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView
Mon, 10 Feb 2025
Earnings Flash (ARWR) Arrowhead Pharmaceuticals Reports Q1 Revenue $2.5M -February 10, 2025 at 04:16 pm EST - Marketscreener.com
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 125 (M) |
Held by Insiders | 1.1049e+008 (%) |
Held by Institutions | 4.4 (%) |
Shares Short | 9,330 (K) |
Shares Short P.Month | 0 (K) |
EPS | -5.2978e+008 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -2 % |
Return on Assets (ttm) | 785 % |
Return on Equity (ttm) | -40.8 % |
Qtrly Rev. Growth | 1.965e+007 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | -163.27 |
EBITDA (p.s.) | 2.1129e+007 |
Qtrly Earnings Growth | -5 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -352 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.12 |
Price to Cash Flow | 6.49 |
Dividend | 0 |
Forward Dividend | 9.45e+006 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |